TearLab Corp fka TEAR

[Wildbilly]

TearLab to Participate in Craig-Hallum's 3rd Annual Alpha Select Conference.
3.9 0.05 (1.30%) @ 4:31PM

TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that its Vice President of Clinical Affairs & Professional Development, David C Eldridge, OD, FAAO, will present an update on the Company's business at the 3rd Annual Craig-Hallum Alpha Select Conference on Thursday, September 27, 2012 at 2:10 p.m. Eastern Time. The conference will be held at the Sentry Centers, New York.

Dr. Eldridge's presentation will be webcast live and archived for approximately 90 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
647.872.4849
[e-mail]